Transport and metabolism of some cationic ubiquinone antioxidants (MitoQn) in Caco-2 cell monolayers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 4, 2008, Pages 199-204

  Li, Yan ^a   Fawcett, Paul J ^a   Zhang, Hu ^a   Tucker, Ian G ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Caco 2 cell monolayers; Metabolism; Mitochondria; MitoQ; Transport; Ubiquinone antioxidant

Indexed keywords

ANTIOXIDANT; CYCLOSPORIN A; MANNITOL; MITOQ10; MITOQ3; MITOQ5; UBIQUINONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL METABOLISM; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MITOCHONDRION; MONOLAYER CULTURE; PROTEIN BINDING; PROTEIN CONTENT; TANDEM MASS SPECTROMETRY;

EID: 59949089354     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190873     Document Type: Article

References (26)

1. James A.M., Cocheme H.M., Smith R.A., Murphy M.P. (2005): Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem. 280, 21295-21312.
2. Murphy, M.P. Smith, R.A. (2007): Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47, 629-656.
3. Asin-Cayuela J., Manas A.R., James A.M., Smith R.A.J., Murphy M.P. (2004): Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 571, 9-16.
4. Ross, M.F., Prime, T.A., Abakumova, I., James, A.M., Porteous, C.M. Smith, R.A.J., Murphy, M.P. (2008): Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem. J. 411, 633-645.
5. Smith R.A.J., Porteous C.M., Gane A.M., Murphy M.P. (2003): Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 5407-5412.
6. Cochemé, H.M., Kelso, G.F., James, A.M., Ross, M.F., Trnka, J., Mahendiran, T., Asin-Cayuela, J., Blaikie, F.H., Manas, A.R., Porteous, C.M., Adlam, V.J., Smith, R.A.J., Murphy, M.P. (2007): Mitochondrial targeting of quinones: Therapeutic implications. Mitochondrion 7S, S94-S102.
7. Adlam, V.J., Harrison, J.C., Porteous, C.M., James, A.M., Smith, R.A.J., Murphy, M.P. Sammut, I.A. (2005): Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 19, 1088-1095.
8. 10, a mitochondria-targeted antioxidant, by Caco-2 cells. J. Pharm. Pharmacol. 59, 503-511.
9. Keepers, Y., Pizao, P., Peters, G., van Ark-Otte, J., Winogad, B., Pinedo, H. (1991): Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 27, 897-900.
10. Li Y., Zhang H., Fawcett J.P., Tucker I.G. (2007): Quantitation and metabolism of mitoquinone, a mitochondria-targeted antioxidant, in rat by liquid chromatography/tandem mass spectrometry. Rapid Comm. Mass Spectrom. 21, 1958-1964.
11. Liberman E.A., Topaly V.P., Tsofina L.M., Jasaitis A.A., Skulachev V.P. (1969): Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 222, 1076-1078.
12. Stein M., Mathers D., Yan H., Baimbridge K., Finlay B. (1996): Enteropathogenic Escherichia coli markedly decreases the resting membrane potential of Caco-2 and HeLa human epithelial cells. Infect. Immun. 64, 4820-4825.
13. Bolduc J.-S., Denizeau F., Jumarie C. (2004): Cadmium-induced mitochondrial membranc-potential dissipation does not necessarily require cytosolic oxidative stress: Studies using Rhodamine-123 fluorescence unquenching. Toxicol. Sci. 77, 299-306.
14. Eytan G.D., Regev R., Oren G., Assaraf Y.G. (1996): The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271, 12897-12902.
15. Litman T., Druley T.E., Stein W.D., Bates S.E. (2001): From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58, 931-59.
16. Troutman, M. D., Thakker, D. R. (2003): Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 20, 1210-1224.
17. Artursson P., Karlsson J. (1991): Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880-885.
18. Aungst B.J., Nguyen N.N., Bulgarelli J.P., Oates-Lenz K. (2000): The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm. Res. 17, 1175-1180.
19. Sawada G.A., Barsuhn C.L., Lutzke B.S., Houghton M.E., Padbury G.E., Ho N.F.H., Raub T.J. (1999): Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J. Pharmacol. Exp. Ther. 288, 1317-1326.
20. Saha P., Kou J.H. (2002): Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur. J. Pharm. Biopharm. 54, 319-324.
21. Artursson P., Palm K., Luthman K. (2001): Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46, 27-43.
22. Fisher J.M., Wrighton S.A., Calamia J.C., Shen D.D., Kunze K.L., Thummel K.E. (1999): Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding, J. Pharmacol. Exp. Ther. 289, 1143-1150.
23. Krishna G., Chen K. W.J., Lin C.C., Nomeir A.A. (2001): Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int. J. Pharm. 222, 77-89.
24. James, A.M., Sharpley, M.S., Manas, A.R., Frerman, F.E., Hirst, J., Smith, R.A.J., Murphy, M.P. (2007): Interaction of the mitochondria-targeted amntioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem. 282, 14708-14718.
25. Sun D., Lennemas H., Welage L., Barnett J., Landowski C., Foster D., Fleisher D., Lee K., Amidon G. (2002): Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400-1416.
26. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L.O., Vyas K.P. (1996): Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. 24, 634-642.